DoD Toxic Exposures Clinical Trial Partnership Award

The summary for the DoD Toxic Exposures Clinical Trial Partnership Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept. of the Army -- USAMRAA, which is the U.S. government agency offering this grant.

DoD Toxic Exposures Clinical Trial Partnership Award: Summary: The intent of the FY25 Toxic Exposures Research Program (TERP) Clinical Trial Partnership Award (CTPA) is to support new or existing collaborative partnerships that will rapidly implement clinical trials with the potential to have a significant impact on the prevention, treatment or management of symptoms, diseases, or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations.Distinctive Features: To encourage applications that include meaningful and productive collaborations between investigators, the FY25 TERP CTPA requires partnership of the Initiating Principal Investigator (PI) with at least one, and up to two, other collaborating PIs for the completion of one overarching study.